Ketotifen Update

Reference List

1 Riccardi VM: Cell-cell interaction as an epigenetic determinant in the expression of mutant neural crest cells. Birth Defects 1979;15(B):89-98.

2 Riccardi VM, Eichner JE: Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. ed 1, Baltimore, Johns Hopkins University Press, 1986.

3 Riccardi VM: Neurofibromatosis: Phenotype, Natural History and Pathogenesis. ed 2, Baltimore, Johns Hopkins University Press, 1992.

4 Merot Y, Banquis C, Saurat J-H: Neurofibromatose de von Recklinghausen et mastocytosis systemique. Dermatologica 1984;168:25-30.

5 Lascano EF: Mast cells in human tumors. Cancer 1958;6:1110-1113.

6 Cawley EP, Hoch-Ligitti C: Association of tissue mast cells and skin tumors. Arch Dermatol 1961;83:92-96.

7 Isaacson P: Mast cells in benign nerve sheath tumors. J Pathol 1976;119:193-196.

8 Yang FC, Chen S, Clegg T, Li X, Morgan T, Estwick SA, Yuan J, Khalaf W, Burgin S, Travers J, Parada LF, Ingram DA, Clapp DW: Nf1+/- mast cells induce neurofibroma-like phenotypes through secreted TGF-beta signaling. Hum Mol Genet 2006;15:2421-2437.

9 Yang FC, Ingram DA, Chen S, Hingtgen CM, Ratner N, Monk KR, Clegg T, White H, Mead L, Wenning MJ, Williams DA, Kapur R, Atkinson SJ, Clapp DW: Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells. J Clin Invest 2003;112:1851-1861.

10 Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF: Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002;296:920-922.

11 Yang F-C, Ingram DA, Chen S, Hingtgen CM, Ratner N, Monk KR, Clegg T, White H, Mead L, Wenning MJ, Williams DA, Kapur R, Atkinson SJ, Clapp DW: Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells. J Clin Invest 2003;112:1851-1861.

12 Ribeiro S, Napoli I, White IJ, Parrinello S, Flanagan AM, Suter U, Parada LF, Lloyd AC: Injury Signals Cooperate with Nf1 Loss to Relieve the Tumor-Suppressive Environment of Adult Peripheral Nerve. Cell Rep 2013;5:1-11.

13 Riccardi VM: The pathophysiology of neurofibromatosis. IV. Dermatologic insights into heterogeneity and pathogenesis. J Am Acad Dermatol 1980;3:157-166.

14 Riccardi VM: Cutaneous manifestations of neurofibromatosis cellular interaction, pigmentation, and mast cells. Birth Defects 1981;17(2):129-145.

15 Tucker T, Riccardi VM, Sutcliffe M, Vielkind J, Wechsler J, Wolkenstein P, Friedman JM: Different patterns of mast cells distinguish diffuse from encapsulated neurofibromas in patients with neurofibromatosis 1. J Histochem Cytochem 2011;59:584-590.

16 Riccardi VM: Mast cell stabilization to decrease neurofibroma growth: preliminary experience with ketotifen. Arch Dermatol 1987;123:1011-1016.

17 Riccardi VM: The potential role of trauma and mast cells in the pathogenesis of neurofibromas; in Ishibashi Y, Hori Y, (eds): Tuberous Sclerosis and Neurofibromatosis: Epidemiology, Pathophysiology, Biology and Management. Amsterdam, Elsevier, 1990, pp 167-190.

18 Riccardi VM: A controlled multiphase trial of ketotifen to minimize neurofibroma-associated pain and itching. Arch Dermatol 1993;129:577-581.

19 Haustein UF: [Ketotifen inhibits urticaria and tumor progression in neurofibromatosis]. Dermatol Monatsschr 1989;175:581-584.

20 Canavese F, Krajbich JI: Resection of plexiform neurofibromas in children with neurofibromatosis type 1. J Pediatr Orthop 2011;31:303-311.

21 Riccardi VM: Ketotifen suppression of NF1 neurofibroma growth over 30 years. Am J Med Genet A 2015;In press DOI 10.1002/ajmg.a.37045.

22 Yamamoto M, Yamauchi T, Okano K, Takahashi M, Watabe S, Yamamoto Y: Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1. Tohoku J Exp Med 2009;217:193-201.

23 Ting S: Ketotifen and systemic mastocytosis. J Allergy Clin Immunol 1990;85:818.

24 Kettelhut BV: Ketotifen in systemic mastocytosis–A response. J Allergy Clin Immunol 1991;87:599.

25 Póvoa P, Ducla-Soares J, Fernandes A, Palma-Carlos AG: A case of systemic mastocytosis: Therapeutic efficacy of ketotifen. J Intern Med 1991;229:475-477.

26 Gallant-Behm CL, Hildebrand KA, Hart DA: The mast cell stabilizer ketotifen prevents development of excessive skin wound contraction and fibrosis in red Duroc pigs. Wound Repair Regen 2008;16:226-233.

27 Soter NA, Austen KF, Wasserman SI: Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med 1979;301:465-469.

28 Monument MJ, Hart DA, Befus AD, Salo PT, Zhang M, Hildebrand KA: The mast cell stabilizer ketotifen reduces joint capsule fibrosis in a rabbit model of post-traumatic joint contractures. Inflamm Res 2012;61:285-292.

29 Monument MJ, Hart DA, Befus AD, Salo PT, Zhang M, Hildebrand KA: The mast cell stabilizer ketotifen fumarate lessens contracture severity and myofibroblast hyperplasia: a study of a rabbit model of posttraumatic joint contractures. J Bone Joint Surg Am 2010;92:1468-1477.

30 Giorno R, Claman HN: Mast cells and neurofibromatosis. Neurofibromatosis 1988;1:100-104.

31 Monk KR, Wu J, Williams JP, Finney BA, Fitzgerald ME, Filippi MD, Ratner N: Mast cells can contribute to axon-glial dissociation and fibrosis in peripheral nerve. Neuron Glia Biol 2007;3:233-244.

32 Naber U, Friedrich RE, Glatzel M, Mautner VF, Hagel C: Podoplanin and CD34 in peripheral nerve sheath tumours: focus on neurofibromatosis 1-associated atypical neurofibroma. J Neurooncol 2010.

33 Xu J, Ismat FA, Wang T, Lu MM, Antonucci N, Epstein JA: Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction. Circ Res 2009;105:304-311.

34 Walker M, Harley R, LeRoy EC: Ketotifen prevents skin fibrosis in the tight skin mouse. J Rheumatol 1990;17:57-59.

35 Vincent L, Vang D, Nguyen J, Gupta M, Luk K, Ericson ME, Simone DA, Gupta K: Mast cell activation contributes to sickle cell pathobiology and pain in mice. Blood 2013;122:1853-1862.

36 Kutlar A: GLEE-ful for sickle cell pain? Blood 2013;122:1846-1847.